UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Exact name of registrant as specified in its charter) Nevada 98-0351734 (IRS Employer (State or other jurisdiction of incorporation or organization) (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT For the transition period from __________ to __________ Commission file n ...

☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 For the transition period from __________ to __________ Form 10-Q (Mark One) Commission file number 001-31392 PLURISTEM THERAPEUTICS INC. ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (Exact name of registrant as specified in its charter) For the quarterly period ended December 31, 2020 (State or other jurisdiction of incorporation or ...

Company Overview - Pluristem Therapeutics is a cell therapy company focused on regenerative medicine, utilizing placenta-derived cell product candidates[5] - The company had approximately $59 million in cash as of June 30, 2020 and employs around 160 full-time employees[5] - Pluristem's technology allows manufacturing of treatments for over 20,000 patients per placenta[11,12,19] Clinical Programs - PLX-PAD aims to treat Critical Limb Ischemia (CLI) by reducing inflammation and stimulating blood vessel growth[28] - A Phase I/II study of PLX-PAD for muscle injury following total hip replacement (N=20) showed a 300% improvement in muscle volume (p=0.004), a 500% improvement in strength compared to the non-operated side (p=0.0067), and a 4000% improvement in strength compared to placebo (p=0.012)[36] - In a compassionate use program, 87.5% survival rate was observed in ventilator-dependent COVID-19 patients treated with PLX-PAD[53] Financials and Partnerships - The EIB (European Investment Bank) signed a €50 million non-dilutive financing agreement with Pluristem to support R&D in the EU[66] - EIB will support up to 50% of the cost of the project[66] - EIB would be entitled to receive royalties from future revenues for a period of seven years starting 2024, at a rate of 0.2% to 2.3%, pro-rated to the amounts that the Company received[67]

Company Presentation May 2020 Forward looking Statement This presentation contains express or implied forward-looking statements within the Private Securities Litigation Reform Act of 1995 and other U.S. Federal securities laws. For example, we are using forward-looking statements when we discuss the expected timing of obtaining regulatory approval for our various patient trials and clinical data readout, proposed trials that may occur in the future, the timing and implementation of our collaborations with ...